Abstract
Hemiarthroplasty becomes the procedure of choice for hip fracture in elderly population with blood loss as its complication. Tranexamic acid (TXA) has been used with no systematic review conducted to evaluate its efficacy and safety. The PRISMA guidelines were followed to conduct literature screening and selection. Main outcomes were extracted for qualitative analysis and quantitative analysis. Blood loss level and haemoglobin drop was significantly reduced in TXA group as compared to the control group. TXA is also deemed as protective factor for transfusion requirement. TXA use may be considered in every patient undergoing hemiarthroplasty procedure unless absolute contraindication exists.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
